Mass spectrometry calibrants
By combining κ or λ light chains as calibrators with mass spectrometry analysis, the problem of difficulty in quantitating monoclonal immunoglobulins and free light chains in the prior art is solved, and high-sensitivity light chain concentration detection is achieved, which improves disease diagnosis. accuracy.
Patent Information
- Application Number
- CN202080034628.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-26
- Filing Date
- 2020-04-29
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-04-29
AI Technical Summary
Existing detection methods are difficult to accurately quantify monoclonal immunoglobulin and free light chains, especially at low concentrations, and there are false negative results, affecting the accuracy of disease diagnosis.
By using κ light chain or λ light chain as calibrator, combined with mass spectrometry (such as LC-MS or MALDI-TOF), the sample is mixed with a predetermined amount of calibrator and mass spectrometry analysis is performed to quantify κ or λ light in the sample. The light chain concentration is calculated using the relative amount ratio.
High sensitivity quantitative detection of monoclonal immunoglobulin and free light chains is achieved, reducing false negative results and improving the accuracy and reliability of disease diagnosis.
Smart Images

Figure BDA0003344662880000121 
Figure BDA0003344662880000122 
Figure BDA0003344662880000131
Abstract
Description
[0001] The present invention relates to the use of kappa light chains or lambda light chains as calibrators to allow quantification of relative lambda or kappa light chains in a sample by mass spectrometry, and to kits containing such calibrators.
[0002] Antibody molecules (also referred to as immunoglobulins) have dual symmetry and are generally composed of two identical heavy chains and two identical light chains, each containing a variable domain and a constant domain. The variable domains of the heavy and light chains combine to form an antigen binding site, so that both chains contribute to the antigen binding specificity of the antibody molecule. The basic tetrameric structure of an antibody comprises two heavy chains covalently linked by a disulfide bond. Each heavy chain, in turn, is connected to a light chain via a disulfide bond. This produces a substantially "Y" shaped molecule.
[0003] The heavy chain is the larger of the two types of chains found in antibodies, with a typical molecular weight of 50,000-77,000 Da, compared to the smaller light chain (25,000 Da).
[0004] There are five major classes or categories of heavy chains, which are gamma, alpha, mu, delta and epsilon, which are the constituent heavy chains of IgG, IgA, IgM, IgD and IgE, respectively. IgG is the major immunoglobulin in normal human serum, accounting for 70-75% of the total immunoglobulin pool. This is the main antibody of the secondary immune response. It forms a single tetramer of two heavy chains plus two light chains.
[0005] IgM accounts for approximately 10% of the immunoglobulin pool. This molecule forms a pentamer of five basic 4-chain structures together with the J chain. A single heavy chain has a molecular weight of approximately 65,000 Da, and the entire molecule has a molecular weight of approximately 970,000 Da. IgM is primarily confined to the intravascular pool and is the predominant early antibody.
[0006] IgA accounts for 15-20% of the human serum immunoglobulin pool. More than 80% of IgA exists as a monomer. However, some IgA (secretory IgA) exists as a dimer.
[0007] IgD makes up less than 1% of total plasma immunoglobulins. IgD is found on the surface membrane of mature B cells.
[0008] Although IgE is absent in normal serum, it is found on the surface membranes of basophils and mast cells. It is associated with allergic diseases such as asthma and hay fever.
[0009] In addition to these five major classes, there are four subclasses of IgG (IgG1, IgG2, IgG3, and IgG4). There are also two subclasses of IgA (IgA1 and IgA2).
[0010] There are two types of light chains: Lambda (λ) and Kappa (κ). In humans, about twice as many κ molecules as λ molecules are produced, but this is quite different in some mammals. Each chain contains about 220 amino acids in a single polypeptide chain that folds into one constant domain and one variable domain. Plasma cells produce one of the five heavy chain types along with either κ molecules or λ molecules. There is usually about a 40% excess production of free light chains compared to heavy chain synthesis. When light chain molecules are not associated with heavy chain molecules, they are referred to as "free light chain molecules." κ chains usually exist as monomers. λ light chains tend to form dimers.
[0011] There are many proliferative diseases associated with antibody-producing cells.
[0012] In many of these proliferative diseases, plasma cells proliferate to form a monoclonal tumor of identical plasma cells. This results in the production of large amounts of identical immunoglobulins and is known as a monoclonal gammopathy.
[0013] Diseases such as myeloma and primary systemic amyloidosis (AL amyloidosis) account for approximately 1.5% and 0.3% of cancer deaths in the UK, respectively. Multiple myeloma is the second most common form of hematological malignancy after non-Hodgkin's lymphoma. In the Caucasian population, the incidence is approximately 40 per million per year. Typically, the diagnosis of multiple myeloma is based on the presence of an excess of monoclonal plasma cells in the bone marrow, monoclonal immunoglobulins in the serum or urine, and associated organ or tissue damage (such as hypercalcemia, renal insufficiency, anemia, or bone lesions). The normal plasma cell content of the bone marrow is about 1%, while in multiple myeloma, this content is usually greater than 10%, often greater than 30%, but can be greater than 90%.
[0014] AL amyloidosis is a protein conformational disease characterized by the accumulation of monoclonal free light chain fragments into amyloid deposits. Typically, these patients present with heart or kidney failure, but peripheral nerves and other organs may also be involved.
[0015] Many other diseases can be identified by the presence of monoclonal immunoglobulins in the patient's bloodstream or even urine. These include plasmacytomas and extramedullary plasmacytomas (plasma cell tumors that arise outside the bone marrow and can occur in any organ). When present, the monoclonal protein is usually IgA. Multiple solitary plasmacytomas can occur with or without evidence of multiple myeloma. Waldenstrom's macroglobulinemia ( Macroglobulinaemia is a low-grade lymphoproliferative disorder associated with the production of monoclonal IgM. There are approximately 1,500 new cases per year in the United States and approximately 300 new cases per year in the United Kingdom. Serum IgM quantification is important for both diagnosis and monitoring. In the United Kingdom, B-cell non-Hodgkin's lymphoma causes approximately 2.6% of all cancer deaths, and monoclonal immunoglobulins have been identified in the serum of approximately 10-15% of patients using standard electrophoretic methods. Initial reports suggest that monoclonal free light chains can be detected in the urine of 60-70% of patients. In B cells, chronic lymphocytic leukemia monoclonal proteins have been identified by free light chain immunoassays.
[0016] In addition, there are so-called MGUS conditions. These are monoclonal gammopathy of undetermined significance. This term refers to the unexpected presence of a monoclonal intact immunoglobulin in an individual with no evidence of multiple myeloma, AL amyloidosis, Waldenstrom's macroglobulinemia, etc. MGUS may occur in 1% of people over 50 years old, 3% of people over 70 years old, and up to 10% of people over 80 years old. Most of these are associated with IgG or IgM, but rarely with IgA or are biclonal. Although most people with MGUS die from unrelated illnesses, MGUS may turn into a malignant monoclonal gammopathy.
[0017] In at least some of the above diseases, there is an abnormal concentration of monoclonal immunoglobulin or free light chains. When the disease produces abnormal replication of plasma cells, this often results in more immunoglobulin being produced by that type of cell as the "monoclonal" multiplies and appears in the blood.
[0018] Immunofixation electrophoresis uses precipitating antibodies against immunoglobulin molecules. Although this increases the sensitivity of the test, it cannot be used to quantify monoclonal immunoglobulins due to the presence of the precipitating antibodies. It is also quite laborious to perform immunofixation electrophoresis, and interpretation can be difficult. Capillary zone electrophoresis is used in many clinical laboratories for serum protein separations and is able to detect most monoclonal immunoglobulins. However, when compared to immunofixation, capillary zone electrophoresis cannot detect monoclonal proteins in 5% of samples. These so-called "false negative" results include low concentrations of monoclonal proteins.
[0019] Serum plasma electrophoresis (SPE) is an alternative procedure that has difficulty identifying proteins below 0.5 g / L and difficulty quantifying proteins below 10 g / L.
[0020] Total kappa and lambda assays have been developed. However, total kappa and total lambda assays are too insensitive to detect monoclonal immunoglobulins, free light chains, or monoclonal free light chains. This is due to the high background concentration of polyclonal bound light chains that interfere with such assays.
[0021] A sensitive assay capable of detecting free kappa light chains and free lambda light chains alone has been developed. The method uses polyclonal antibodies against free kappa light chains or free lambda light chains. The possibility of producing such antibodies is also discussed in WO97 / 17372 as one of many different possible specificities. The document discloses methods of tolerizing animals to allow them to produce more specific desired antibodies than can be produced by the prior art. The free light chain assay uses antibodies to bind free lambda light chains or free kappa light chains. The concentration of free light chains is determined by turbidimetry or nephelometry. This involves adding the test sample to a solution containing the appropriate antibody in a reaction vessel or cuvette. A light beam passes through the cuvette, and as the antigen-antibody reaction proceeds, the light passing through the cuvette is increasingly scattered as insoluble immune complexes are formed. In nephelometry, light scattering is monitored by measuring the intensity of light at a certain angle to the incident light, while in turbidimetry, light scattering is monitored by measuring the decrease in the intensity of the incident light beam. A series of calibrants of known antigen (ie free kappa or free lambda) concentrations are first assayed to generate a calibration curve of measured light scatter versus antigen concentration.
[0022] This format of the assay has been found to successfully detect free light chain concentrations. Furthermore, the sensitivity of the technique is very high.
[0023] Characterization of the amount or type of free light chains (FLC), heavy chains or subclasses, or the type of light chains associated with heavy chain classes or subclasses is important in a wide range of diseases, including B cell disorders such as multiple myeloma and other immune-mediated diseases such as renal disease.
[0024] WO 2015 / 154052 discloses a method for detecting immunoglobulin light chains, immunoglobulin heavy chains or mixtures thereof using mass spectrometry (MS), which is incorporated herein in its entirety. A sample containing immunoglobulin light chains, heavy chains or mixtures thereof is immunopurified and subjected to mass spectrometry to obtain a mass spectrum of the sample. This can be used to detect monoclonal proteins in samples from patients. It can also be used for fingerprinting, isotypes and identification of disulfide bonds in monoclonal antibodies.
[0025] MS is used to separate, for example, lambda chains and kappa chains in a sample by mass and charge. It can also be used to detect the heavy and light chain components of immunoglobulins, for example by reducing the disulfide bonds between the heavy and light chains using a reducing agent. MS is also described in WO2015 / 131169, which is incorporated herein in its entirety.
[0026] Purification of immunoglobulins from samples in diagnostic procedures typically uses anti-whole antibodies, such as anti-IgG, anti-IgA, anti-IgM, anti-IgD, anti-IgE, anti-total kappa, anti-total lambda antibodies, or anti-free light chain antibodies, such as anti-free kappa or anti-free lambda light chain antibodies. It is important to have calibrators to ensure that the purification and detection process is performed correctly.
[0027] WO2017 / 144900 describes a number of controls using a heavier form of the analyte to be detected or a monoclonal of the analyte to be detected. That is, for example, IgA can be quantified compared to a predetermined amount of heavier IgAκ.
[0028] In some mass spectrometry methods (such as MALDI-TOF), the target protein is crystallized on the mass spectrometry target. The degree of crystallization of any single protein is variable across the target. In addition, the properties of individual proteins mean that crystallization on the target is variable between proteins. Therefore, it is expected that different proteins will crystallize on the mass spectrometry target at different rates. This means that when the matrix is sampled by mass spectrometry, different amounts of control protein and analyte will be detected.
[0029] In addition, their ionization rates (for MALDI-TOF or other techniques that do not require crystallization, such as liquid chromatography-mass spectrometry (LC-MS)) are expected to be different. Mass spectrometry requires ionization of the target molecule. Ionization depends on the properties of the individual proteins. Therefore, it is expected that different proteins will ionize differently, resulting in inconsistent amounts of immunoglobulins detected.
[0030] Unexpectedly, Applicants have discovered that kappa and lambda light chains crystallize and ionize at substantially identical rates, such that the calibration range for a lambda or kappa light chain is proportional to other kappa or lambda light chains crystallized on the matrix, or ionized during mass spectrometry analysis.
[0031] This allows quantification of kappa light chains in a sample using either lambda light chains as calibrators, or lambda light chains and kappa light chains as calibrators, respectively.
[0032] The present invention provides a method for quantifying the amount of kappa or lambda immunoglobulin light chain in a sample from a subject, comprising:
[0033] i. Providing a sample from a subject;
[0034] ii. mixing the sample with a predetermined amount of a lambda light chain calibrator or a kappa light chain calibrator to form a mixture;
[0035] iii. performing mass spectrometry analysis on the mixture; and
[0036] iv. Quantify one or both of the following:
[0037] a. quantifying the amount of lambda light chains in the sample by comparing the relative amount of lambda light chains in the mixture determined by mass spectrometry with the relative amount of calibrator kappa light chains in the mixture determined by mass spectrometry; and / or
[0038] b. quantifying the amount of kappa light chains in the sample by comparing the relative amount of kappa light chains in the mixture as determined by mass spectrometry to the relative amount of calibrator lambda light chains in the mixture as determined by mass spectrometry.
[0039] Mass spectrometry analysis is typically LC-MS or MALDI-TOF mass spectrometry.
[0040] The amount of kappa light chains can be the amount of polyclonal kappa light chains or monoclonal kappa light chains in the sample. The amount of lambda light chains can be the amount of polyclonal lambda light chains or monoclonal lambda light chains in the sample. The amount can be the concentration of polyclonal lambda or kappa light chains in the sample.
[0041] The kappa or light chains in the sample can bind to one or more immunoglobulin heavy chains.
[0042] The lambda light chain or the kappa light chain of the calibrator may be bound to one or more immunoglobulin heavy chains prior to mixing with the sample.
[0043] That is, the kappa or lambda light chain can be provided, for example, as IgGkappa, IgGlambda, IgAlambda, IgAkappa, IgMlambda, IgMkappa, IgDlambda, IgDkappa, IgElambda, or IgEkappa.
[0044] Alternatively, the kappa or lambda light chains in the sample may be free kappa or lambda light chains. The calibrator lambda or light chains may be free light chains. In the latter case, these may be added after the immunoprecipitation step with anti-heavy chain antibodies.
[0045] The lambda or kappa light chains in the calibrator can be monoclonal. Alternatively, they can be derived from polyclonal antibodies. Polyclonal antibodies are particularly preferred. This is because some differences in ionization or crystallization patterns are expected between different monoclonal antibodies. It is expected that the use of polyclonal antibodies will reduce the noise of using a single monoclonal calibrator and produce more consistency with the method of the present invention.
[0046] The lambda light chains in the calibrator or the kappa light chains in the calibrator may or may not be mass-changed. They may have their molecular weight or charge increased or decreased to allow the peaks in the mass spectrometry readings of the analyte to change compared to the equivalent kappa or lambda light chains in the sample. For example, WO 2017 / 144900 describes a variety of methods for changing the molecular weight or charge of the calibrator lambda or calibrator kappa light chains, including isotope labeling of antibodies or adding one or more amino acids to the antibodies. If a monoclonal antibody has, for example, a different light chain mass than the light chain of the sample, then the monoclonal antibody may also be selected.
[0047] Many monoclonal antibodies are commercially available, such as from Sigma Aldrich in the United Kingdom under the trade name SILu TM Lite monoclonal antibodies. These include, for example, SILu TM Lite stable isotope universal monoclonal antibodies as well as non-isotope labeled monoclonal antibodies.
[0048] The calibrator antibody can be modified in mass with, for example, polyethylene glycol (PEG) via a protein reactive group such as N-hydroxysuccinamide (NHS) or maleimide (e.g., maleimide PEG 3.4 kDa). A preferred mass modifier is pentafluorophenyl polyethylene glycol (PFP-PEG), which the applicant has found to be particularly useful as a mass modifier for immunoglobulin light chains. Another preferred mass modifier is the use of an indole-butyric acid derivative conjugated to a nucleotide binding site. Such modifiers are commercially available with lengths different from the PEG chain, for example, up to a mass of 20 kDa.
[0049] When a calibrator kappa light chain or a calibrator lambda light chain can be distinguished from the same light chain type in a sample by mass spectrometry, the amount of the calibrator light chain identified by mass spectrometry can also be used to quantify the amount of the same type of light chain in the sample. That is, the lambda calibrator light chain can be used to quantify not only the kappa light chain in a sample, but also the lambda light chain in a sample, and the kappa light chain can be used to determine not only the lambda light chain in a sample, but also the kappa light chain in a sample. They may be distinguishable because the observed m / z can be distinguished using monoclonal light chain calibrators or calibrators of different masses.
[0050] Typically, the mixture is purified in at least one purification step prior to mass spectrometry analysis.By using a calibrator with the mixture, this acts as an internal calibrator or "internal reference calibrator" to account for any losses of sample immunoglobulins during purification or other manipulation of the sample.
[0051] Samples can be processed to remove components that may interfere with, for example, mass spectrometry techniques. For example, samples can be centrifuged, filtered, or subjected to chromatographic techniques to remove interfering components, for example, from multiple cells or a cell or tissue fragment. For example, conventional coagulation techniques can be used to process whole blood samples to remove red blood cells and white blood cells and platelets. For example, using conventional reagents such as acetonitrile, KOH, NaOH, optionally followed by centrifugation of the sample, plasma samples can precipitate serum proteins. Immunoglobulins, for example, can be separated from samples or enriched in samples using standard methods. Such methods include, for example, removing one or more non-immunoglobulin contaminants from samples. Alternatively, immunopurification, centrifugation, filtration, water filtration, dialysis, ion exchange chromatography, size exclusion chromatography, protein A / G affinity chromatography, affinity purification, precipitation, gel electrophoresis, capillary electrophoresis, or chemical fractionation can be used to enrich or purify samples.
[0052] Typically, a calibrator is added to a sample as an internal reference calibrator before at least one of these purification techniques. That is, for example, by the above method, before the purification or concentration of immunoglobulins in a sample is performed, it is included in the analyte sample of the object. That is, typically, before using a technique other than the mass spectrometry method for detecting the analyte, for example, by LC-MS, electrospray mass spectrometry, orbital trap MS or MALDI-TOF MS. The advantage of being incorporated into the sample is that the calibrator analyte acts as an internal reference calibrator in the purification process of the sample. A known amount of calibrator or fragment is added to the sample, and this can be used as a positive internal reference calibrator, which can also be used to confirm that the purification step has been successful, or for identifying problems that occur during the purification process of the analyte in the object sample. Using an internal reference calibrator allows determination to become a quantitative determination.
[0053] The sample or mixture may be immunopurified. Typically, the sample is mixed with the calibrator to form a mixture prior to the immunopurification step. The calibrator may also be added after the immunopurification step.
[0054] The immunopurification step may utilize one or more of the following: anti-heavy chain class-specific antibodies, anti-total light chain class-specific antibodies, anti-free light chain class-specific antibodies, or anti-heavy chain class-light chain class-specific antibodies or fragments thereof. Such antibodies are generally known in the art.
[0055] The antibodies may be heavy chain subclass specific or light chain specific or heavy chain class-light chain type specific.
[0056] Anti-heavy chain class-light chain type specific or heavy chain subclass-light chain type specific antibodies are sold under the trade name Hevylite TMCommercially available from The Binding Site Limited, Birmingham, United Kingdom. Such heavy chain class-light chain type specific antibodies include, for example, IgGκ specific antibodies and IgGλ specific antibodies.
[0057] The antibody or fragment may be anti-IgG specific, anti-IgA specific, anti-IgD specific, anti-IgM specific, anti-IgE specific.
[0058] Antibodies specific to total lambda, total kappa, free lambda or free kappa may be used. Calibrators may be added after this immunopurification.
[0059] The antibody may be an anti-human specific antibody.
[0060] The sample may be a biological sample, such as blood, serum, plasma, cerebrospinal fluid or urine, more typically blood, serum or plasma.
[0061] The sample may be from a subject exhibiting hypogammaglobulinemia or hypergammaglobulinemia. The subject may suffer from a proliferative disease associated with antibody-producing cells, such as a monoclonal gammopathy. These include myeloma and primary systemic amyloidosis, plasmacytoma, Waldenstrom's macroglobulinemia, and MGUS.
[0062] The sample can be treated with a reducing agent before mass spectrometry analysis. This is particularly useful when the light chains in the sample, and indeed often the calibrants, are bound to immunoglobulins. The use of a reducing agent decouples the light chains from the heavy chains and allows the light chains to be detected separately by mass spectrometry analysis.
[0063] Decoupling can be achieved by treating the total immunoglobulin with a reducing agent, such as DTT (2,3-dihydroxybutane-1,4-dithiol), DTE (2,3dihydroxybutame-1,4dithiol), thioglycolate (salt), cysteine, sulfite, bisulfite, sulfide, disulfide, TCEP (tris (2-carboxyethyl) phosphine), 2-mercaptoethanol and its salt forms. In some embodiments, the reduction step is carried out at an elevated temperature, for example at about 30° C. to about 65° C., such as about 55° C., to denature the protein.
[0064] The decoupling step is typically performed following immunopurification or other enrichment of immunoglobulins in a sample, or as part of an elution step following immunopurification of the sample.
[0065] The antibodies used for immunopurification can be intact antibodies or fragments thereof, such as Fab, F(ab) and F(ab') 2Fragments or single chain antibodies.
[0066] When the antibody or fragment comprises a light chain and a heavy chain or a fragment of such a chain, they can be cross-linked to reduce contamination of the sample by the antibody or fragment used in immunopurification. Methods for cross-linking such antibodies are described in detail in WO2017 / 144900 (which is incorporated herein by reference in its entirety).
[0067] The method of the present invention may include comparing the relative amount of the λ light chain in the sample identified by mass spectrometry to the relative amount of the calibrator κ light chain, or the relative amount of the κ light chain in the sample to the relative amount of the calibrator λ light chain, to allow the calculation of the amount of the λ light chain or κ light chain in the sample. The ratio of the height (peak intensity) of the relative peak of the sample light chain to the calibrator light chain can be used. Alternatively, the ratio of the area (peak area) of the peak from the sample light chain to the peak area of the calibration light chain can be used. The applicant has also found that by comparing the peak area of λ or κ from the sample with the combined area of λ or κ from the sample plus the area from the calibrator κ or λ peak, the accuracy is improved.
[0068] The relative ratio between sample and calibrator can be identified by generating a calibrator curve of the amount of kappa to lambda light chains via mass spectrometry using known amounts of light chains.
[0069] The ratio of kappa to lambda light chains in a sample can be determined.
[0070] The present invention also provides a computer comprising a machine-readable medium adapted to receive a first signal indicating the amount of a kappa light chain in a sample or the amount of a lambda light chain in a sample, and a second signal indicating the amount of a lambda light chain calibrator or a kappa light chain calibrator obtained by a method according to the present invention, and comparing the two signals with a predetermined calibration factor to indicate the amount of a kappa light chain or a lambda light chain in the sample. The calibration factor may be obtained in advance using a calibration curve.
[0071] The kit used in the present invention comprises one or more of the following:
[0072] (a) anti-IgG specific antibody and a predetermined amount of IgGκ or IgGλ immunoglobulin;
[0073] (b) anti-IgA specific antibody and a predetermined amount of IgAκ or IgAλ immunoglobulin;
[0074] (c) anti-IgM specific antibody and a predetermined amount of IgMκ or IgMλ immunoglobulin;
[0075] (d) anti-IgD specific antibody and a predetermined amount of IgDκ or IgDλ immunoglobulin; or
[0076] (e) anti-IgE specific antibodies and a predetermined amount of IgEκ or IgEλ immunoglobulin;
[0077] The kits and methods of the present invention may also include the use of standard human serum or the presence of standard human serum in the kit, such as DA470K. This is a standardized human serum prepared according to the ERM standard DA470K and can be used as a calibrant. It contains α2 macroglobulin, α1 acid glycoprotein, α1 antitrypsin, albumin, β2-microglobulin, complement proteins C3c and C4, haptoglobulin, immunoglobulins IgA, IgG and IgM, a mixture of transferrin and transthyretin.
[0078] The present invention also provides a method for quantifying the amount of heavy chains in a sample, which comprises providing a sample from a subject, separating immunoglobulins from the sample by immunopurification with an anti-total κ antibody or an anti-total λ antibody, and adding IgM heavy chains as calibrators before performing mass spectrometry analysis, and quantifying the amount of IgG in the sample determined by mass spectrometry analysis.
[0079] In this case, the antibody purifies heavy chains bound to either lambda or kappa light chains. IgM is used as a calibrator because it is glycosylated and therefore has a different m / z value and can therefore be used as a calibrator.
[0080] The mass spectrometry analysis and other components of the method may be as described above.
[0081] The invention will now be described, by way of example only, with reference to the following drawings.
[0082] Figure 1A SiLuLite IgG1λ is shown as an internal reference (calibrator) added to the same MALDI mass spectrometer together with a sample from a patient with IgGκ multiple myeloma. Figure 1B The relationship between the MALDI peak intensity ratio of the calibrator and the sample versus the IgG1κ concentration is shown.
[0083] Figure 2A SiLuLite IgG4κ is shown as an internal reference (calibrator) added to the same MALDI mass spectrometer together with a sample from a patient with IgGλ multiple myeloma. Figure 2B The relationship between the MALDI peak intensity ratio of calibrator and sample versus IgG1λ concentration is shown.
[0084] Figure 3 Shown are the peak area ratios of equal amounts of purified polyclonal IgGκ and IgGλ mixed together prior to immunoprecipitation and MALDI-TOF analysis.
[0085] Figure 4AShown is purified monoclonal IgAλ as an internal reference (calibrator) spiked onto the same MALDI mass spectrometer together with a sample from a patient with IgA1κ multiple myeloma. Figure 4B The relationship between the MALDI peak intensity ratio of the calibrator and the sample versus the IgA1κ concentration is shown.
[0086] Figure 5 The relationship between the MALDI-TOF peak area ratios of polyclonal IgGκ (calibrator) mixed with polyclonal IgGλ as analyte is shown.
[0087] Figure 6 Shown is the use of polyclonal IgGκ as calibrator and monoclonal SiLuLite IgGλ as analyte in the range of 0-2 g / L.
[0088] In each of these embodiments, internal reference (or calibrator) protein is added to the analyte of different concentrations at a fixed concentration. Substrate-specific immunoprecipitation is performed on each sample using paramagnetic beads coated with polyclonal anti-IgG or anti-IgA. After light chain is separated from heavy chain, a MALDI-TOF mass spectrometer is used to obtain a light chain mass spectrum. Peak signal intensity or peak area of every combination is measured, and then it is plotted for the concentration of the analyte (sample).
[0089] Commercially available and quality-assured SiLu TM Lite IgG1λ was used as an internal reference and G1K13 M-spike (IgG1κ) was used as a sample. The two light chain m / z peaks were clearly separated from each other in the mass spectrum ( Figure 1A ), and a strong correlation was observed between the peak intensity ratio and the concentration of the monoclonal protein sample ( Figure 1B ), where the peak intensity ratio is the ratio of the peak intensity of the lambda light chain of the reference calibrant material to the peak intensity of the kappa light chain from the IgG kappa monoclonal protein in the sample. TM Lite IgG4κ was used as an internal reference calibrator and the analyte sample was G1L08 M-spike (IgG1λ) with very similar results ( Figure 2A and B). These results have shown that a monoclonal IgG of either a kappa or lambda light chain can be used as a calibrant for MALDI-TOFMS of another monoclonal IgG of the opposite light chain.
[0090] To test whether the intensity peak area between κ and λ light chains is constant, equal amounts of purified polyclonal IgGκ and polyclonal IgGλ were mixed together and diluted. The diluted samples were then immunoprecipitated using anti-IgG antibodies immobilized on beads and reduced to separate the κ and λ light chains from the IgG heavy chains before being spotted onto a MALDI target plate. The plate was then subjected to mass spectrometry analysis and the polyclonal light chain peak areas for κ and λ light chains were determined and plotted as a function of concentration (Table 1 and Table 2). Figure 3 The results showed that the peak area (κ to λ) ratio was constant over a 10-fold concentration range (7.44 to 0.74 g / L) and was not significantly affected by ionization or differential binding to anti-IgG antibodies on the beads.
[0091]
[0092] To demonstrate that this effect was not heavy chain class specific, a monoclonal IgA1κ antibody was used as an internal reference and IgAλ was used as a sample. The two light chain m / z peaks were again clearly separated from each other in the mass spectrum ( Figure 4A ), and a strong correlation was observed between the peak intensity ratio and the concentration of the monoclonal protein sample ( Figure 4B ). This suggests that the ability to use λ or κ as calibrants is not heavy chain class specific.
[0093] Figure 5 The use of a polyclonal light chain as an internal reference relative to a polyclonal light chain is shown. This example uses polyclonal IgGκ as a calibrator or internal reference and poly IgGλ as an analyte. The peak area ratios obtained for the calibrator and samples in the range of 9.9 to 0.2 g / L sample concentration are shown in the table below and plotted on Figure 5 middle.
[0094]
[0095]
[0096] Figure 6 The ability to use polyclonal light chains as calibrators for monoclonal light chains as analytes was demonstrated. 0.5 g / L of purified polyclonal IgGκ was used as an internal reference and mixed with SiLuLite IgGλ monoclonal protein ranging from 2.0-0.1 g / L. The peak area ratios obtained for the calibrators and samples are shown in the table below and in Figure 6 Plotted against sample concentration.
[0097] These examples have shown that different combinations of immunoglobulin kappa or lambda containing molecules can be used as internal reference or calibrator molecules for other immunoglobulins relative to light chains in MALD-TOFMS. This utility is valid for both monoclonal and polyclonal proteins.
[0098]
Claims
1. A method for quantifying the amount of kappa or lambda immunoglobulin light chain in a sample from a subject, comprising: i. Providing a sample from a subject; ii. mixing the sample with a predetermined amount of a lambda light chain calibrator or a kappa light chain calibrator to form a mixture; iii. performing mass spectrometry analysis on the mixture; and iv. Quantify one or both of the following: a) quantifying the amount of lambda immunoglobulin light chains in said sample by comparing the relative amount of lambda immunoglobulin light chains in said mixture as determined by said mass spectrometry with the relative amount of calibrator kappa light chains in said mixture as determined by mass spectrometry; and / or b) quantifying the amount of kappa immunoglobulin light chains in said sample by comparing the relative amount of kappa immunoglobulin light chains in said mixture as determined by mass spectrometry to the relative amount of calibrator lambda light chains in said mixture as determined by mass spectrometry.
2. The method according to claim 1, wherein the mass spectrometry analysis is MALDI-TOF spectroscopy or liquid chromatography-mass spectrometry.
3. The method of claim 1, wherein the calibrator is a polyclonal lambda light chain or a polyclonal kappa light chain.
4. The method of claim 1, wherein the calibrator is a monoclonal kappa light chain or a monoclonal lambda light chain.
5. The method of claim 1, wherein the kappa or lambda immunoglobulin light chain in the sample is associated with one or more immunoglobulin heavy chains.
6. The method of claim 1, wherein the lambda light chain or kappa light chain of the calibrator is bound to one or more immunoglobulin heavy chains prior to mixing. The method according to claim 1 , wherein the kappa or lambda immunoglobulin light chain in the sample is a free kappa or lambda immunoglobulin light chain.
8. The method of claim 1, wherein the lambda light chain or kappa light chain in the calibrator is a free light chain.
9. The method of claim 1, wherein the lambda light chain in the calibrator or the kappa light chain in the calibrator is mass altered.
10. The method of claim 9, wherein the calibrator has one or more additional amino acids compared to the kappa immunoglobulin light chain or the lambda immunoglobulin light chain in the sample, or is linked to polyethylene glycol.
11. The method of claim 1, wherein the mixture is purified in at least one purification step prior to mass spectrometry analysis.
12. The method of claim 1, wherein the sample or mixture is immunopurified.
13. The method according to claim 12, wherein the sample or mixture is immunopurified using anti-heavy chain class-specific antibodies, anti-total light chain class-specific antibodies, anti-free light chain class-specific antibodies or anti-heavy chain class-light chain class-specific antibodies or fragments thereof.
14. The method of claim 13, wherein the antibody is anti-IgG specific, anti-IgA specific, anti-IgD specific, anti-IgM specific, or anti-IgE specific.
15. The method of claim 13, wherein the antibody is anti-total λ specific, anti-total κ specific, anti-free λ specific, or anti-free κ specific.
16. The method according to claim 12, wherein the sample or mixture is immunopurified using an anti-human specific antibody.
17. The method of claim 1, wherein the sample is selected from the group consisting of: blood, serum, plasma, cerebrospinal fluid, and urine.
18. The method of claim 17, wherein the sample is selected from the group consisting of blood, serum and plasma.
19. The method of claim 5, comprising treating the sample or mixture with a reducing agent prior to mass spectrometry analysis.
20. The method of claim 1, comprising calculating the ratio of the relative amount of λ immunoglobulin light chains in the sample to the relative amount of κ light chains of the calibrator, or calculating the ratio of the relative amount of κ immunoglobulin light chains in the sample to the relative amount of λ light chains of the calibrator.
21. The method of claim 20, comprising calculating the ratio of the peak area of the λ or κ immunoglobulin light chain from the sample to the peak area of the calibrator κ or λ light chain, or calculating the ratio of the peak area of the λ or κ immunoglobulin light chain from the sample to the combined area of the λ or κ immunoglobulin light chain from the sample plus the area of the calibrator κ or λ light chain peak.
22. The method of claim 1, wherein the calibrator kappa light chain or calibrator lambda light chain can be distinguished from the same immunoglobulin light chain type in the sample by mass spectrometry, and the amount of the calibrator light chain identified by mass spectrometry is used to quantify the amount of the same type of light chain in the sample.
23. The method of claim 1, wherein the ratio of kappa to lambda immunoglobulin light chains in the sample is measured.
24. The method of claim 1, wherein the subject has a B cell proliferative disorder.
25. The method of claim 24, wherein the subject has a monoclonal gammopathy.
26. The method according to any one of claims 1 to 25, wherein the method is performed using a kit comprising an antibody selected from: (f) anti-IgG specific antibodies and a predetermined amount of IgGκ or IgGλ immunoglobulin; (g) anti-IgA specific antibody and a predetermined amount of IgAκ or IgAλ immunoglobulin; (h) anti-IgM specific antibody and a predetermined amount of IgMκ or IgMλ immunoglobulin; (i) anti-IgD specific antibody and a predetermined amount of IgDκ or IgDλ immunoglobulin; or (j) anti-IgE specific antibody and a predetermined amount of IgEκ or IgEλ immunoglobulin.
27. A computer comprising a machine-readable medium adapted to receive a first signal indicating the amount of κ immunoglobulin light chains in a sample or the amount of λ immunoglobulin light chains in the sample, and a second signal indicating the amount of λ light chain calibrator or κ light chain calibrator obtained by a method according to any one of the preceding claims, and compare the first signal and the second signal with a calibration factor pre-obtained using a calibration curve to indicate the amount of κ immunoglobulin light chains or λ immunoglobulin light chains in the sample.
